Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunosuppressive medication in multiple sclerosis].

J A García Merino1

  • 1Servicio de Neurología, Clínica Puerta del Hierro, Madrid, España. gmerino@meditex.es

Revista De Neurologia
|December 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case report: Primary cytomegalovirus infection in a patient with late onset multiple sclerosis treated with dimethyl fumarate.

Frontiers in neurology·2024
Same author

Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.

PloS one·2016
Same author

Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Journal of neurology·2010
Same author

[Units of multiple sclerosis in Spanish public hospitals: are they feasible and necessary?].

Neurologia (Barcelona, Spain)·2002
Same author

Bilateral facial paralysis secondary to trichinosis.

Acta neurologica Scandinavica·1988
Same author

[Ankylosing spondylitis with mononeuritis and possible multiple sclerosis (author's transl)].

Medicina clinica·1980
Same journal

The Correlation Between and Variability of Three Balance Scales in the Assessment of Balance Function in Patients With Ataxia.

Revista de neurologia·2026
Same journal

Surgical Treatment of an Aneurysm in the Subacute Stage of Hemorrhagic Moyamoya Disease: Aneurysm Resection Combined With STA-MCA Bypass: A Case Report.

Revista de neurologia·2026
Same journal

Mapping the Evidence: Central Sleep Apnea Syndromes During Sleep and Stroke-A Scoping Review.

Revista de neurologia·2026
Same journal

Developmental and Epileptic Encephalopathy Due to a Novel <i>ARHGEF9</i> Deletion Variant: Case Series of Two Siblings.

Revista de neurologia·2026
Same journal

P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.

Revista de neurologia·2026
Same journal

[Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache].

Revista de neurologia·2026
See all related articles

Immunosuppressive drugs remain vital for multiple sclerosis (MS) treatment, even with new immunomodulators. Research reviews their use, alone or combined with immunomodulators, for better MS management.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Context:

  • Multiple sclerosis (MS) treatment has evolved significantly with the introduction of immunomodulators.
  • Immunosuppressive drugs, including newer agents like mitoxantrone, continue to play a role in MS management.
  • Traditional efficacy studies for immunosuppressants often used outdated criteria, complicating current assessment.

Purpose:

  • To review the established use of immunosuppressive drugs in multiple sclerosis (MS).
  • To discuss the potential role of immunosuppressants in combination therapy with immunomodulators.
  • To explore future therapeutic options involving immunosuppressive agents for MS.

Summary:

  • Immunosuppressive drugs have a long history in treating multiple sclerosis (MS).

Related Experiment Videos

  • Despite the advent of immunomodulators, immunosuppressants like mitoxantrone are still relevant.
  • Assessing the precise indications for these drugs is challenging due to historical study limitations.
  • Immunosuppressants may offer benefits when used alongside immunomodulators in MS therapy.

    • Impact:

    • Provides a comprehensive overview of immunosuppressant utility in MS.
    • Highlights the need for updated research to define optimal use of immunosuppressants.
    • Informs clinical decisions regarding combination therapies for multiple sclerosis.
    • Guides future research directions for immunosuppressive treatments in MS.